expression ranged from 399 genes in OV to 4,795 genes in testicular germ cell tumours (TGCTs; Fig. 3b). Alterations of miRNA expression ranged from 2 in skin cutaneous melanoma (SKCM) to 213 in THYM. Stomach adenocarcinoma (STAD) showed the largest number of alterations at the protein level, while THYM showed the largest number of alterations in DNA methylation and BRCA showed the largest number of SCNAs. The total number of hypoxia-associated features across multiple layers also varied. For example, STAD had many hypoxiaassociated features in six molecular layers, including 4,169 mRNAs, 186 miRNAs, 91 proteins, 294 methylation probes, 1 gene mutation and 10 SCNAs, while glioblastoma multiforme (GBM) had hypoxia-associated features in 629 mRNAs and 5 proteins. Furthermore, previous studies demonstrated the effects of hypoxia status on metabolomics. Based on 399 metabolites from 23 TCGA BRCA samples, we observed that 86 metabolites positively correlated with hypoxia score (r > 0.3, P < 0.05; Supplementary Fig. 4a). We further identified 45 metabolites that were upregulated in 7 hypoxia score-high samples compared to 6 hypoxia score-low samples (two-sided Student's t-test, P < 0.05; Supplementary Fig. 4b). These results provide an overview of the molecular differences associated with hypoxia status across tumour lineages.4243sTo assess the potential effects of hypoxia-associated features on drug response, we focused on 1,060 genes with at least 1 type of hypoxia-associated molecular signature in at least 9 cancer types. We calculated Spearman's rank correlations between the expression of these genes and drug sensitivity for 252 anticancer drugs from the Genomics of Drug Sensitivity in Cancer (GDSC) across 1,074 cancer cell lines. These anticancer drugs target multiple biological processes, including the chromatin signature, cell cycle, metabolism, EGFR signalling and receptor tyrosine kinase (RTK) signalling pathways. We identified 143 hypoxia-associated genes that significantly correlated with the sensitivity of at least three anticancer drugs (|r| > 0.3, FDR < 0.05; Fig. 3c, Supplementary Fig. 5 and Supplementary Data 2). For example, the protein level of transcriptional coactivator YAP1 is upregulated in hypoxia score-high samples in nine cancer types; its mRNA expression is linked to drug resistance to 49 anticancer drugs (for example, navitoclax, r = 0.52, FDR < 1.0 × 10) and linked to drug sensitivity to five anticancer drugs in (for example, docetaxel, r = −0.42, FDR = 1.7 × 10). Dysregulation of the RTK signalling pathway is an established feature in multiple cancer types and RTK signalling can be stimulated44ss−55s−35
expression ranged from 399 genes in OV to 4,795 genes in testicular germ cell tumours (TGCTs; Fig. 3b). Alterations of miRNA expression ranged from 2 in skin cutaneous melanoma (SKCM) to 213 in THYM. Stomach adenocarcinoma (STAD) showed the largest number of alterations at the protein level, while THYM showed the largest number of alterations in DNA methylation and BRCA showed the largest number of SCNAs. The total number of hypoxia-associated features across multiple layers also varied. For example, STAD had many hypoxiaassociated features in six molecular layers, including 4,169 mRNAs, 186 miRNAs, 91 proteins, 294 methylation probes, 1 gene mutation and 10 SCNAs, while glioblastoma multiforme (GBM) had hypoxia-associated features in 629 mRNAs and 5 proteins. Furthermore, previous studies demonstrated the effects of hypoxia status on metabolomics. Based on 399 metabolites from 23 TCGA BRCA samples, we observed that 86 metabolites positively correlated with hypoxia score (r > 0.3, P < 0.05; Supplementary Fig. 4a). We further identified 45 metabolites that were upregulated in 7 hypoxia score-high samples compared to 6 hypoxia score-low samples (two-sided Student's t-test, P < 0.05; Supplementary Fig. 4b). These results provide an overview of the molecular differences associated with hypoxia status across tumour lineages.4243s<br><br>To assess the potential effects of hypoxia-associated features on drug response, we focused on 1,060 genes with at least 1 type of hypoxia-associated molecular signature in at least 9 cancer types. We calculated Spearman's rank correlations between the expression of these genes and drug sensitivity for 252 anticancer drugs from the Genomics of Drug Sensitivity in Cancer (GDSC) across 1,074 cancer cell lines. These anticancer drugs target multiple biological processes, including the chromatin signature, cell cycle, metabolism, EGFR signalling and receptor tyrosine kinase (RTK) signalling pathways. We identified 143 hypoxia-associated genes that significantly correlated with the sensitivity of at least three anticancer drugs (|r| > 0.3, FDR < 0.05; Fig. 3c, Supplementary Fig. 5 and Supplementary Data 2). For example, the protein level of transcriptional coactivator YAP1 is upregulated in hypoxia score-high samples in nine cancer types; its mRNA expression is linked to drug resistance to 49 anticancer drugs (for example, navitoclax, r = 0.52, FDR < 1.0 × 10) and linked to drug sensitivity to five anticancer drugs in (for example, docetaxel, r = −0.42, FDR = 1.7 × 10). Dysregulation of the RTK signalling pathway is an established feature in multiple cancer types and RTK signalling can be stimulated44ss−55s−35
正在翻译中..